Nature Reviews Cardiology

Article	Citations
The future of cardiac xenotransplantation	726
Congenital heart disease and risk of severe COVID	485
PPARα regulates the development and inflammation of vein graft lesions	483
GRK5 linked to cardiac dysfunction and leukocyte recruitment after MI	450
Social disparities in COVID-19 prevention	446
FFR-guided PCI vs CABG surgery in multivessel CAD	436
Electronic alerts can PROMPT guideline-directed care for HFrEF	425
α-Myosin-specific CD8+ T cells drive ICI-related myocarditis	396
Non-fatal MI as surrogate end point for all-cause or cardiovascular mortality	356
Physicians in the era of technology-enabled diagnostics	342
Smartwatch detection of left ventricular dysfunction	294
Immediate non-inferior to staged complete revascularization	277
Intravascular imaging improves outcomes	264
Hidden disparities in the rising prevalence of bystander cardiopulmonary resuscitation	232
Cost-effective benefit of iron-replacement therapy	217
Sacubitril–valsartan shows benefit in heart failure with ejection fraction of >40%	216
Antibody treatment to deplete transthyretin amyloid deposits in the heart	200
Targeting ALK1 to block LDL transcytosis and halt atherosclerosis	198
Pacing with respiratory sinus arrhythmia improves outcomes in heart failure	188
Targeting the adipose tissue to protect the heart	180
Truncated titin proteins in the pathophysiology of DCM	176
Basophils promote healing after MI	162
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications	159
Injectable and conductive cardiac patch	155
Self-monitoring strategy reduces postpartum hypertension and cardiac remodelling	145

Base editing therapy corrects long QT syndrome in mice	142
PCI for stable angina	141
Pulsed-field ablation: a revolution in atrial fibrillation therapy	140
Revealing the structure of the cardiac myosin filament	140
Mentorship in cardiology: building the mentoring relationship	138
Functional testing after PCI in high-risk patients	130
Oxygen and BP targets for OHCA	127
Hypertension in China: epidemiology and treatment initiatives	118
Benefit of vutrisiran in transthyretin amyloidosis with cardiomyopathy	118
Clonal haematopoiesis: an emerging causal risk factor for atherosclerotic CVD	117
RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia	116
Aggregation of big tau disrupts microtubules and causes diastolic dysfunction	116
Benefits of ninerafaxstat in non-obstructive hypertrophic cardiomyopathy	114
No benefit of β-blockers after myocardial infarction with preserved ejection fraction	114
LIPC variant in combined hypocholesterolaemia	108
No benefit of colchicine to prevent AF or myocardial injury after non-cardiac surgery	107
Guidelines to lower intake of added sugar are necessary and justified	107
CAS and CEA have similar risks and benefits	105
Limited benefit of triglyceride lowering with fibrates in statin-treated patients	99
Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF	98
Carotid stenosis management: time to address the misconceptions (‘furphies’)	92
Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases	89
Iron deficiency and supplementation in heart failure	89
Applications of artificial intelligence in cardiovascular imaging	87
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals	84
Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease	84
Three different therapies to target PCSK9	84
Illusion of revascularization: does anyone achieve optimal revascularization during percutaneous coronary intervention?	82
The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction	81
Genetics and mechanisms of thoracic aortic disease	81
Macrophages in cardiac remodelling after myocardial infarction	81
The spleen in ischaemic heart disease	79
Blood pressure and its variability: classic and novel measurement techniques	79
Haematometabolism rewiring in atherosclerotic cardiovascular disease	75
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?	74
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective	74
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	72
Electroimmunology and cardiac arrhythmia	72
Inclusion of remnant cholesterol improves risk prediction for ischaemic heart disease	72
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	71
The use of new CRISPR tools in cardiovascular research and medicine	69
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development	65
Sex-related similarities and differences in responses to heart failure therapies	60
Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention	59
Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved	58
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	57
Social determinants of atrial fibrillation	56
Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease	54
Author Correction: Optical coherence tomography in coronary atherosclerosis assessment and intervention	53
2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease	52

A roadmap of strategies to support cardiovascular researchers: from policy to practice	51
Sit less and move more for cardiovascular health: emerging insights and opportunities	51
Publisher Correction: Cardiac involvement in the long-term implications of COVID-19	51
IRONMAN adds support for iron repletion in HF	50
Vascular endothelial cell development and diversity	50
Strategies to prevent burnout in the cardiovascular health-care workforce	49
Universal flu vaccines: a shot at lifelong cardioprotection?	48
Current and future applications of virtual reality technology for cardiac interventions	48
Travelling with heart failure: risk assessment and practical recommendations	48
A fresh look at coronary microembolization	48
Cardiac optogenetics: controlling the heart with light	47
The need for increased pragmatism in cardiovascular clinical trials	47
Defining iron deficiency in patients with heart failure	46
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	46
AI outperforms sonographers at diagnosing cardiac function on echocardiography	45
Self-expanding valves more beneficial than balloon-expandable valves in patients with a small aortic annulus	45
Heterogeneity of the post-infarct epicardium	43
Anti-IL-1β therapy lowers leukocyte supply and uptake in atherosclerosis	42
Abbreviating DAPT reduces the risk of bleeding	42
Macrophage OLFR2 activation is atherogenic	42
Sirtuin 2 protects against cardiac ageing	39
Mending broken hearts with the help of epigenetic remodellers	39
Resurgence of renal denervation for resistant hypertension	38
Blocking endothelial lipase raises HDL-C levels	38
CD200 is an atheroprotective immune checkpoint	38
Vitamin K antagonists for RHD-associated AF	37
Polypills for the secondary prevention of MACE	36
Cardiovascular benefits of statins outweigh small risk of muscle pain	33
A proteomic model shows potential as a surrogate end point for CVD risk	32
Diversity in human genetics studies accelerates discovery and improves health care	31
Glucocorticoid receptor inhibition promotes cardiac repair after MI	31
Promising findings for cell therapy in HFrEF	30
Trials and tribulations of cell therapy for heart failure: an update on ongoing trials	29
Boosting mitochondrial metabolism with dietary supplements in heart failure	29
Clinical and subclinical acute brain injury caused by invasive cardiovascular procedures	28
Cardiodermatology: the heart of the connection between the skin and cardiovascular disease	28
Consequences of ionizing radiation exposure to the cardiovascular system	28
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium	27
PPAR control of metabolism and cardiovascular functions	27
Immune and inflammatory mechanisms in hypertension	26
Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges	24
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications	24
Immune cell profiling in atherosclerosis: role in research and precision medicine	24
Alternative defibrillation strategies improve outcomes	23
Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization	23
An all-virtual clinical trial to assess a heart failure drug	23
Flow-induced reprogramming of endothelial cells in atherosclerosis	23
Gout flares can precede cardiovascular events	22
Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease	22
Ablation plus pacing strategy reduces mortality in patients with AF and HF	20
Levothyroxine supplementation does not improve heart transplantation from brain-dead donors	20
Targeted therapies for cardiac diseases	20
New insights into OCT-guided PCI	19
The cardiac parasympathetic system has two parallel circuits	19
Age-induced senescence impairs the neurovascular interface in the heart	19
Explaining how a cardiac reflex causes syncope	19
Complete revascularization in MI: role in older patients and optimal timing	19
Electron microscopy of cardiac 3D nanodynamics: form, function, future	18
Innate lymphoid cells improve recovery of cardiac function after MI	18
Left atrial appendage occlusion	18
Inhibiting aldosterone synthase reduces blood pressure	17
Selective JAG1–NOTCH3 targeting shows potential for treating PAH	16
Cryoballoon ablation reduces AF progression	16
MicroRNA directly modulates cardiac ion channel	16
Artificially transplanted mitochondria in endothelial cells promote mitophagy	15
Obstructive sleep apnoea heterogeneity and cardiovascular disease	14
Cardiac fibroblasts and mechanosensation in heart development, health and disease	14
Epidemiology of cardiovascular disease in Europe	13
Update on the pathophysiology and medical treatment of peripheral artery disease	13
Pathophysiology and risk factors of peripartum cardiomyopathy	12
Ultra-processed foods and cardiovascular disease	12
Bioengineering approaches to treat the failing heart: from cell biology to 3D printing	12
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases	12
Hallmarks of cardiovascular ageing	11
Cardiovascular physiology and pathophysiology at high altitude	11
The rapid delayed-rectifier potassium current: a biophysical basis for cardiac repolarization and arrhythmia	10
The role of aldehyde dehydrogenase 2 in cardiovascular disease	10
Effective CRISPR modulation of complex non-coding RNA loci	10
Modulating the gut microbiota with dietary interventions to protect against cardiometabolic disease	10
Pathophysiological insights into HFpEF from studies of human cardiac tissue	10

A newly identified gut hormone suppresses cholesterol production in the liver

10